1. Home
  2. MOB vs SPRO Comparison

MOB vs SPRO Comparison

Compare MOB & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobilicom Limited

MOB

Mobilicom Limited

N/A

Current Price

$5.87

Market Cap

73.8M

Sector

Real Estate

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.22

Market Cap

71.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOB
SPRO
Founded
2008
2013
Country
Israel
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
71.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
MOB
SPRO
Price
$5.87
$1.22
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
125.2K
1.3M
Earning Date
03-23-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$150.10
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$4.33
$1.08
52 Week High
$11.01
$3.08

Technical Indicators

Market Signals
Indicator
MOB
SPRO
Relative Strength Index (RSI) 56.53 35.20
Support Level $5.46 $1.10
Resistance Level $6.74 $1.29
Average True Range (ATR) 0.51 0.06
MACD 0.05 0.04
Stochastic Oscillator 48.06 46.67

Price Performance

Historical Comparison
MOB
SPRO

About MOB Mobilicom Limited

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: